Key facts
- This page summarizes Andreas Wicki's Form 4 filing for Harmony Biosciences Holdings, Inc. (HRMY).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2021, 20:46.
Andreas Wicki - 08 Dec 2021 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)
- Reporting relationship
- Director
- Issuer ticker
- HRMY
- Reported as of
- 08 Dec 2021
- Net transaction value
- -$1,093,148
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2021, 20:46:03 UTC
- Prior SEC filing
- 17 Nov 2021
- Next SEC filing
- 04 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mehdi Khodadad, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andreas Wicki filed Form 4 for Harmony Biosciences Holdings, Inc. (HRMY) on 10 Dec 2021.
Change
- Previous filing in this sequence was filed on 17 Nov 2021.
- Current net transaction value: -$1,093,148.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRMY
transaction
Common Stock
Sale
- Transaction value
- $989,541
- Shares
- -24,683
- Change %
- -0.54%
- Price
- $40.09
- Shares after
- 4,547,828
- Date
- 08 Dec 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
HRMY
transaction
Common Stock
Sale
- Transaction value
- $103,607
- Shares
- -2,585
- Change %
- -0.06%
- Price
- $40.08
- Shares after
- 4,545,243
- Date
- 10 Dec 2021
- Ownership
- See Footnote
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.37, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
Footnote F2
These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.09, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.